Table 4.

Cumulative analysis of mir608:rs4919510 and mir219-1:rs213210 in stage III patients receiving fluoropyrimidine-based chemotherapy

No. of Variant Genotypes	No recurrence, n (%)	Recurrence, n (%)	HR(95%CI)	P value*
Training set
0	78(80.41)	19(19.59)	1(reference)
1	52(71.23)	21(28.77)	2.97(1.40-6.28)	0.004
2	3(60.00)	2(40.00)	10.48(2.02-54.47)	0.005
p for trend				0.0006
Replication set
0	3(5.36)	53(94.64)	1(reference)
1	1(2.50)	39(97.50)	1.63(0.98-2.70)	0.06
2	1(16.67)	5(83.33)	3.41(1.21-9.58)	0.02
P for trend				0.01
Combined set
0	81(52.94)	72(47.06)	1(reference)
1	53(46.90)	60(53.10)	1.67(1.12-2.49)	0.01
2	4(36.36)	7(63.64)	3.53(1.51-8.26)	0.004
P for trend				0.001
	Alive, n (%)	Dead, n (%)
Training set
0	86(88.66)	11(11.34)	1(reference)
1	57(78.08)	16(21.92)	7.49(2.38-23.56)	0.0006
2	4(80.00)	1(20.00)	14.98(1.36-164.94)	0.03
P for trend				0.0001
Replication set
0	21(37.50)	35(62.50)	1(reference)
1	17(42.50)	23(57.50)	2.04(1.04-4.01)	0.04
2	2(33.33)	4(66.67)	7.34(2.03-26.52)	0.002
P for trend				0.003
Combined set
0	107(69.93)	46(30.07)	1(reference)
1	74(65.49)	39(34.51)	2.51(1.47-4.28)	0.001
2	6(54.55)	5(45.45)	5.60(1.91-16.45)	0.002
P for trend				5.25×10−5

^*Adjusted for age, gender, ethnicity, smoking status, tumor site, histologic grade, and treatment